OV329 / TAK-935 (Soticlestat)
Dravet Syndrome, Lennox-Gastaut Syndrome
Phase 3Licensed to Takeda; Phase 3 trials ongoing
Key Facts
Indication
Dravet Syndrome, Lennox-Gastaut Syndrome
Phase
Phase 3
Status
Licensed to Takeda; Phase 3 trials ongoing
Company
About Ovid Therapeutics
Ovid Therapeutics is a clinical-stage biopharmaceutical company with a mission to transform the lives of patients with rare neurological disorders. The company leverages its expertise in brain biology to develop targeted therapies for conditions like Angelman syndrome, CDKL5 deficiency disorder, and developmental and epileptic encephalopathies. Ovid's strategy involves both internal development and strategic partnerships to advance its pipeline. The company is publicly traded and has established collaborations with leading research institutions and biotech partners.
View full company profile